Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 , a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Fathom Nickel Announces Filing of NI 43-101 Technical Report for Previously Announced Maiden Mineral Resource Estimate, Gochager Lake Ni-Cu-Co Deposit, Saskatchewan
CoTec Holdings Corp. Notes HyproMag USA Secures Power and Advances Project Readiness for Texas Rare Earth Magnet Recycling and Manufacturing Hub
Renforth Extends Surface Gold Mineralization In Channels On Wholly Owned Parbec Gold Deposit In Malartic, Quebec
